Skin manifestations in spondyloarthritis

Katharina Meier, Alexandra Schloegl, Denis Poddubnyy and Kamran Ghoreschi

Abstract: Spondyloarthritides (SpA) like psoriatic arthritis, axial spondyloarthritis/ankylosing spondylitis, reactive arthritis and inflammatory bowel disease (IBD)-associated SpA can present with characteristic skin manifestations. These SpA-associated skin disorders may precede joint involvement, reflect a loss of efficacy of a current systemic treatment or can even be treatment associated. Cutaneous manifestations in SpA not only add additional morbidity with physical impact but also impose a psychosocial burden on affected patients. Psoriasis (PsO) – the main skin disease in SpA – has a variety of clinical presentations, including plaque-type PsO, inverse PsO, guttate PsO, erythrodermic PsO, nail PsO and pustular types. SpA associated with IBD presents with neutrophilic and granulomatous skin disorders, including pyoderma gangrenosum, hidradenitis suppurativa and cutaneous Crohn’s disease. Reactive arthritis has a favourable prognosis and may feature keratoderma blenorrhagicum or balanitis circinatum as typical skin manifestations. Immunologically, SpA-associated skin diseases share interleukin (IL)-17 and IL-23 dysregulation but show distinctive genetic and immunological profiles. Therefore, they vary in their treatment responses to targeted therapies with biologicals or small molecules. In this review, we highlight the clinical presentation of skin manifestations in SpA and discuss therapeutic approaches in this interdisciplinary field.

Keywords: erythema nodosum, hidradenitis suppurativa, psoriasis, psoriatic arthritis, pyoderma gangrenosum, skin, spondyloarthritis

Received: 6 September 2020; revised manuscript accepted: 3 November 2020.

Introduction
Spondyloarthritis (SpA) is one of the most common rheumatic diseases, affecting up to 1.9% of the population.1 It describes a variety of chronic inflammatory conditions that affect primarily the axial skeleton with the sacroiliac joints and the spine, but may also present with peripheral joint involvement. SpA can be further distinguished into non-radiographic and radiographic axial SpA [the latter also known as ankylosing spondylitis (AS)], psoriatic arthritis (PsA), SpA associated with inflammatory bowel diseases (IBD) and reactive arthritis (ReA).2 Progressive spinal stiffness along with chronic back pain are the most common symptoms of axial involvement, whereas asymmetrical joint stiffness and pain along with dactylitis and enthesitis, mono- or oligo-arthritis, mainly in lower extremities, define the peripheral inflammatory joint diseases. All of them are associated with distinct extra articular manifestations affecting the gastrointestinal system with IBD, anterior uveitis (AU) of the eye and various diseases of the skin.3

Genetic links between the aforementioned diseases include positivity for the major histocompatibility complex human leucocyte antigen B27 (HLA-B27) allele and genetic polymorphisms within genes of the Th17/interleukin (IL)-23 pathway.4 These factors play a major role in the inflammation causing SpA and associated diseases.5–7

In this review, we focus on the skin manifestations associated with SpA, and state-of-the-art treatments based on currently approved drugs for inflammatory disorders. Finally, we provide some insights regarding progress achieved in the understanding of these disorders and related future therapeutics.8

Psoriasis
Psoriasis (PsO) is one of the most common inflammatory skin diseases, with an estimated prevalence of 0.6–4.8% of the global population.9,10 Patients typically present with characteristic erythematous plaques with a coarse overlying...
scale on specific sites such as elbows, knees, scalp, umbilicus, rima ani and palms. The transition from a cutaneous to a synovio-entheseal disease affects about one-third of PsO patients, who develop a PsA over time.\textsuperscript{11} PsO precedes joint involvement on average by 7 years (range 0–20 years), creating a unique opportunity for early intervention in populations at risk.\textsuperscript{12,13} The importance of early diagnosis and early intervention in articular disease is highlighted by the fact that a delay of 6 months in initiating PsA treatment already can cause peripheral joint erosions, with subsequent impairment of joint function.\textsuperscript{13,14} In peripheral SpA patients, an early anti-tumour necrosis factor (TNF) treatment leads to a remarkable sustained clinical remission. This shows that there is a window of opportunity in the course of inflammatory diseases.\textsuperscript{14} Therefore, a thorough clinical examination of joints and the whole skin by dermatologists and rheumatologists is key to allow early intervention.\textsuperscript{15} Ideally, selected patients should be seen in interdisciplinary medical settings.

PsO is a frequent and early manifestation of SpA.\textsuperscript{16} About one-third of SpA patients are affected by PsO. On the other hand, a significant number of PsA patients are asymptomatic concerning back pain, but show radiographic signs of axial involvement.\textsuperscript{17} In SpA, PsO most frequently presents as a plaque-type disease (66.7%), which is the commonest form of PsO in general. Also, scalp involvement is very common in SpA patients (65.5%). Psoriasis pustulosa palmoplantaris (20.2%) and nail PsO (19.1%) are described in four out of five patients.\textsuperscript{16} Of note, nail involvement, psoriasis capitis and inverse psoriasis have been reported to show an increased risk for PsA.\textsuperscript{18–20}

The diagnosis of PsO is generally a clinical diagnosis based on its characteristic morphological appearance. There are no specific blood tests recommended and a skin biopsy is rarely needed. Psoriasis vulgaris refers to the classic plaque type PsO (PV), initially with erythematous macules and papules coalescing to well demarcated erythematous silver-white scaly round plaques on the body with a symmetrical predilection on the elbows and knees, the dorsum of the hands and feet, scalp, umbilicus and rima ani (Figure 1).

Mild psoriasis is treated by topical agents like vitamin D analogs (calcipotriol, tacalcitol) and corticosteroids. In flexural sites, or on the face, either calcipotriol or non-steroidal topicals like pimecrolimus or tacrolimus (off-label) are recommended to avoid corticosteroid-induced skin atrophy. Phototherapy with narrow-band ultraviolet (UV)B and topical dithranol are effective, but usually used in inpatient settings for treatment initiation because application is inconvenient in a domestic setting. Further systemic treatments with methotrexate, fumarates and acitretin are generally considered as first line and cost effective.\textsuperscript{21,22} Although cyclosporine is generally recommended in guidelines, it should not be used due to its toxicities and pro-tumorigenic aspects. As the aforementioned agents are generally rarely effective in SpA, they will not be discussed in this review.

Inverse PsO

In contrast to psoriasis vulgaris, inverse PsO affects the flexural sites and intertriginous areas. Most common affected skin sites are axillae, inguinal folds, inframammary and perineal regions. Clinically, an inverse PsO presents with sharply edged erythematous and mildly elevated plaques with little or no scales and occasionally rhagades, and therefore is easily confused with candida or dermatophytic intertrigo (Figure 1D). Inverse psoriasis affecting the genitals significantly affects the patient’s quality of life.

Guttate PsO

Guttate PsO often presents with an acute onset of multiple small round erythematous plaques on the trunk and extremities. The term guttata refers to droplets (‘gutta’) representing the small plaques, which are less than 1 cm in size and usually present monomorphically due to a timely similar onset of the lesions (Figure 1C). PsO guttata is associated with streptococcal infections of the throat, especially in children and young adults. Although PsO guttata has a favorable prognosis, it may also appear as the first manifestation of an underlying chronic plaque PsO.\textsuperscript{23–25} About one-third of patients will develop classical PsO over time.\textsuperscript{25} Although streptococcal infections are often associated, there is no reproducible data on the efficacy of antibiotic treatment to give general recommendations. Yet, some patients may benefit from antistreptococcal antibiotics or tonsillectomy. A rapid involving course is associated with younger age, higher anti-streptolysin titres and a negative family history for PSO.\textsuperscript{25,26}
If the majority of the body surface (>80–90%) is affected with erythematous maculae or plaques, an erythrodermic PsO is a concerning differential diagnosis. It is associated with hypothermia, fevers with dehydration and tachycardia and often displays with peripheral oedema. Abrupt discontinuation of systemic treatments, especially corticosteroids or PsO-triggering medication such as lithium or beta blockers, can lead to this more exanthematus clinical picture. In this case, skin biopsies are helpful to rule out differential diagnosis like pityriasis rubra pilaris, an erythroderma drug rash, a cutaneous T cell lymphoma or an atopic dermatitis. In addition, in Fitzpatrick skin types V and VI visualizing the erythema can be challenging (Figure 1B).

**Figure 1.** Clinical presentation of PsO. [A] PV; [B] erythrodermic PsO; [C] guttate PsO; and [D] inverse PsO. PsO, psoriasis; PV plaque PsO.
Nail PsO
The spatial proximity of the inflammation in the nail bed and matrix along with the enthesitis suggests a close relationship of nail involvement and enthesitides. Up to 80% of PsA patients show nail involvement, and nails are affected in more than half of all PsO patients. In fact, almost all patients with proof of ultrasonic enthesitis show nail abnormalities. PsO of the nail may present without classic skin manifestations. While nail PsO of the finger shows a very typical picture, toenails might present only with subungual hyperkeratosis, which is seen regularly in onychomycosis and therefore an important differential.

Psoriasisform nail changes include changes of the nail matrix, such as pitting, nail plate crumbling, leukonychia and red spots in the lunula. Pitting, irregular deep small depressions in the nail plate, is highly characteristic of nail PsO and reflects a focal parakeratinization in the proximal nail matrix, leaving nucleated cells in the upper cornified layers. If the nail bed is affected subungual hyperkeratosis, splinter haemorrhages, oil drop dyschromia and onycholysis is shown (Figure 2C, D).

The treatment of nail PsO still is a challenging and tedious process since nail renewal takes several months. Topical therapies usually underperform. Calcipotriol ointment, intralesional and topical corticosteroid show no, or limited, effects. Nail PsO should be treated with systemic drugs when it has a high impact on quality of life and presents with functional impairment.

Pustular PsO, palmoplantar pustular PsO and acrodermatitis continua of hallopeau
Neutrophilic accumulation is histologically found as microabscesses in the skin of psoriatic plaques. Macroabscesses form clinically visible pustules. Pustular PsO (PP) presents mostly with an acute onset of multiple small-sized sterile pustules on an erythematous base. Its generalised form [generalised pustular psoriasis (GPP)], with rapidly evolving monomorphic pustules coalescing to confluent pustules, is a rare but serious condition with fevers, myalgia and elevated inflammatory serum markers. Causally, abrupt corticosteroid withdrawal, infections, certain drugs and pregnancy have to be evaluated. Further, impaired liver function, hypocalcemia and dehydration may appear and complicate the condition. In GPP, mutations within the IL36RN or CARD14 genes have been found that promote inflammatory cell recruitment by keratinocytes and uncontrolled release of inflammatory cytokines. However, only a minority of PP are actually caused by IL36RN mutation and PV-associated PP correlates with this mutation in only 17%. Despite the genetic association with the IL-36 pathway, all forms of pustular PsO are characterised by an increased transcriptional expression of IL-1β, IL-36α, and IL-36γ compared with PV. The IL-17 axis plays also an important role in PP, independent of IL36RN mutation status.

A severe pustulosis affecting the tips of fingers and toes is called acropustulosis or acrodermatitis continua of Hallopeau (ACH). It generally affects nail growth, from severe onychodystrophy up to anonychia, and may lead to osteolysis of the distal phalanx (Figure 2C).

A manifestation of palmoplantar pustular PsO (PPP) features erythematous plaques with multiple sterile pustules on the palms and soles, demarcated mostly by a thin red ring and scales (Figure 2A, B). PPP is the most common of the pustular PsO types. It is more common in females and smokers and may present as a paradoxical skin manifestation in patients without a history of PsO that are treated with anti-TNF-α therapeutics, for example, inflammatory joint diseases or IBD.

The treatment of all pustular PsO types is challenging and there is a need for treatments with proven efficacy.

IBD-associated skin manifestations in spondyloarthritis
Crohn’s disease (CD) and ulcerative colitis (UC) are chronic IBDs, which can present with several extra intestinal manifestations (EIM) that affect mortality and morbidity. Up to 50% of IBD patients experience at least one EIM. EIM of the skin typically appear years after the first diagnosis of an IBD, whereas axSpA and uveitis can manifest before the diagnosis of IBD. More than one-third of patients with CD and up to 15% of patient with UC present with EIM, and more than 10% of all Crohn’s patients present with cutaneous manifestations. Within the latter group, erythema nodosum (EN), pyoderma gangrenosum (PG) and psoriasis are the most common EIM.
Figure 2. Clinical presentation of PsO affecting the hands and feet. (A) Plantar PsO with hyperkeratotic plaques (left and middle) and pustular presentation (right). (B) Palmar PsO with hyperkeratotic plaques (left and middle) and pustular presentation (right). (C) Acrodermatitis continua of Hallopeau with severe onychodystrophy and oil drop dyschromia (*). (D) Nail PsO with onychodystrophy, pitting (*) and onycholysis (°). PsO, psoriasis.
Pyoderma gangrenosum

PG are rare chronic or recurrent cutaneous ulcers that typically present with a necrolytic undermined violaceous border rising rapidly from a papule or pustule of the skin (Figure 3). The incidence of PG is described as 3–10 per million per year, with a female predilection, occurring mainly in mid-adulthood. It may occur idiopathically, in association with inflammatory diseases such as IBD or as inherited inflammatory syndrome, such as PAPA (pyogenic arthritis, PG, and acne), PASH (PG, acne, and hidradenitis suppurativa), or PAPASH (pyogenic arthritis, acne, PG, and hidradenitis suppurativa). Histologically, it shows a massive sterile neutrophilic infiltrate but often lacks a fibrinoid necrosis of blood vessels and therefore represents a neutrophilic dermatosis along with Behçet’s disease, hidradenitis suppurativa and Sweet syndrome. Nonsyndromic PG shows a decrease in regulatory T cells and an increase in IL-17 in affected skin facilitating the recruitment of neutrophils. Syndromic PG has been recently classified as auto-inflammatory diseases with inflammasome activation leading to excessive IL-1β, TNF-α and IL-8 production. Interestingly, this signature has also been found in nonsyndromic PG.

A retrospective cohort study aiming to investigate comorbidities in PG showed that 20.5% of all PG patients were affected by inflammatory arthritides defined as RA, PsA, and AS. Most commonly, PG is associated with IBD, especially UC, but also hematologic malignancies have been described. In IBD associated PG, IBD should be treated first. Pathergy is a well-known trigger mechanism in PG and postsurgical reoccurrence is published regularly.

There are various therapeutic approaches but, due to disease rarity, controlled clinical trials are lacking. Systemic corticosteroids are most frequently used for treatment initiation. For long-term immunosuppression in PG cyclosporine, infliximab, mycophenolat mofetil, azathioprine, intravenous immunoglobulins and methotrexate as well as cyclophosphamide have been reported. Although there is an excessive infiltration with neutrophils, anti-neutrophilic therapies with dapsone or colchicine showed limited efficacy and are used as adjunct agents.

Erythema nodosum

Erythema nodosum (EN) is the most commonly reported cutaneous manifestation in rheumatic diseases and IBD. It presents clinically as painful, often symmetric erythematous plaques and nodules on the extensor surfaces, mainly of the lower limbs (Figure 4). The clinical presentation is often classical but can be clinically challenging when it lacks the symmetrical appearance or its nodular...
aspect. In this case, differential diagnoses such as a cutaneous CD, a cellulitis due to a bacterial infection and cutaneous lymphoma should be considered and a biopsy should be taken. Histologically, EN presents as a septal panniculitis, characterized by septal fibrosis with infiltration of lymphocytes, neutrophils (especially in the early phase), histiocytes and granulomas with giant cells. In most cases, EN is self-limiting when the underlying disease is being treated. Since EN often presents painful, anti-inflammatory analgesics and compression are a helpful supportive treatment. In more severe cases, systemic corticosteroids up to 1 mg/kg/day are recommended and generally lead to a rapid improvement. EN may also present as a manifestation of an infection with *Mycobacterium tuberculosis* or as a symptom of a manifest tuberculosis. Especially in the scope of reactivations of latent tuberculosis in patients treated with TNF-α inhibitors, this rare differential diagnosis has to be considered.

**Cutaneous CD**

Cutaneous CD (cCD) – often referred to metastatic CD – is a very rare disease with less than 100 reported cases since its first description in 1956. It presents in tissues noncontiguous with the intestine and histologically presents, as CD, with non-caseating epitheloid cell granulomas with various giant cells reaching into the deep dermis. It often shows a perivascular lymphohistiocytic infiltrate with plasma cells. Clinically, it presents as erythematous swollen plaques or nodules that may ulcerate and discharge pus (Figure 5). Due to its rarity, there are no clinical trials regarding treatment of cCD. Topical and intralesional corticosteroids may be used for small lesions, while, for larger lesions oral antibiotics, especially metronidazole, traditional immunosuppressive agents and surgery, have shown mixed results. For systemic treatment, biologics should be used as known from classic CD treatment.

**Hidradenitis suppurativa**

Hidradenitis suppurativa (HS) is a strongly impairing chronic inflammatory disease affecting primarily apocrine gland-bearing areas such as the groin and axillaries. HS leads, via recurrent painful deep tissue inflammation, to purulent discharge and debilitating scars and is associated with a massive impact on quality of life (Figure 6). Affecting 1–4% of the general population, it is a rather common disease with an association with smoking and overweight. It is three times more common in females and affects generally young adults.

The clinical presentation can be challenging. On average, HS patients see more than three physicians and it takes about 10 years from first symptoms to the final diagnosis. HS shows an association with a variety of skin diseases, such as acne conglobate and neutrophilic dermatoses. Recent transcriptomic analysis supported the hypothesis that the underlying pathogenic mechanism of these diseases link to an infiltrate of neutrophils and macrophages in affected tissues and increased levels of inflammatory cytokines IL-1α, IL-1β, IL-17A/F, IL-23 and TNF-α, an involvement of the JAK–STAT pathway and genetic variants of B-cell co-stimulation, such as CXCR5. In lesional skin of HS patients, frequencies of CD4+ T cells expressing IL-17 and
TNF were elevated significantly and anti-TNF treatment resulted in a significant reduction of IL-17 expressing CD4+ T cells in HS skin.71

Importantly, 2–28% of HS patients show an axial involvement, and almost 10% of patients with axSpA develop a HS. Their temporally correlating appearance reflects a possible immunogenic link.72–74 In SpA patients, HS precedes the diagnosis of SpA in most cases and axial involvement is frequent within this group, which also shares a strong HLA-B-27 positivity.72 Since SpA patients with axial involvement and HS tend to have a higher disease activity, clinical screening for HS in SpA patients is crucial.75 On the other hand, HS patients with lower back pain and dactylitis or other oesteoarticular symptoms should be screened for SpA.74 Besides IBD and inflammatory arthropathies, common comorbidities of HS are cardiovascular disease, diabetes mellitus, metabolic syndrome, polycystic ovary syndrome, depression and anxiety and these conditions should be regularly screened in HS patients.76

The treatment of HS is mostly an interdisciplinary approach, with surgical, topical and systemic treatments and supportive therapies such as analgesics, especially nonsteroidal anti-inflammatory drugs (NSAIDs) and weight reduction and smoking cessation.76,77 Topical therapies focusing on, and antibiotic strategies to reduce, bacterial triggered inflammation as well as keratolytic ointments reducing follicular clogging are considered as initial treatments, intralesional corticosteroid injections are considered as second-line therapies and should be used only for acutely inflamed HS lesions.76

Guidelines recommend oral tetracyclines as first-line therapy and should be administered over a minimum period of 12 weeks.78,79 Coadministration of clindamycin and rifampicin over at least 4 weeks is a common long-term treatment, although there is low evidence that the combination reduces the presumed antibiotic resistances.80 Retinoids, especially acitretin and dapsone, are recommended as third-line therapies in most guidelines. A systemic treatment does benefit inflammation, with a decrease of nodules and discharge, but does not benefit fistulas. A surgical evaluation therefore is key to efficacious treatment of moderate-to-severe HS.

Reactive arthritis (ReA) is defined as a form of peripheral SpA occurring after an infection affecting not primarily the joint, most commonly of the gastrointestinal or genitourinary tract. ReA frequently affects young adults and is five times more common in individuals with a positive HLA-B27 genotype.81 HLA-B27-related ReA presents in a more chronic manner, with frequent extra-articular manifestations and an unfavorable prognosis compared with non HLA-B27 ReA.82 In up to 50% of patients, it presents with distinct dermatological manifestations such as keratoderma blenorrhagicum (KB) and circinate balanitis (CB), may show an ulcerative vulvitis, nail changes, oral lesions and conjunctivitis. Since symptoms occur 1–4 weeks after the causing infection, microbial swaps and cultures often remain negative, but microbial DNA and RNA have been found in affected joints.83,84 Pathomechanistically, it is rather a stimulation of inflammatory cytokines by bacterial antigens and its immune-mediated reaction. Depending on the region, sex and age group, Chlamydia trachomatis, Enterobacteriae and Campylobacter, Yersinia and Shigella are well known causes.85,86

CB is characterised by vesicles and pustules of the glans penis developing into small annular painless erosions and is very common (Figure 7A). In circumcised males, it may present more hyperkeratotic. Ulcerative vulvitis shows a similar pattern on small labia and the vulva, and is often associated with vaginal discharge.85 KB typically manifests at the plantae and palmae, beginning with erythematous macules and papules rising into vesicular, often hyperkeratotic plaques and sterile pustules (Figure 7B). It presents in about 10% of HLA-B27-positive ReA patients. Nail and mucosal changes are common.88

ReA is frequently self-limiting, and first line treatment is generally with NSAIDs.89 Treatment of cutaneous symptoms are similar to other inflammatory cutaneous diseases and often respond to topical corticosteroids and keratolytics. The use of long-term antibiotics has been controversially been discussed.90 Biologics rapidly improve skin and joint manifestations but relapses are common after discontinuation.91 There has been a broad spectrum of the use of anti-inflammatory biologics with an emerging role of the IL-17/IL-23 pathway.92
Paradoxical skin reactions to biologicals
Paradoxical skin reactions (PSR) in patients being treated with targeted biologicals appear with a prevalence of 0.6–5.3% in the general population, and are most common within patients being treated with TNF-α-antagonists. They have to be considered when new cutaneous lesions occur during targeted- or immune-modulating therapies in immune-mediated inflammatory diseases. PSR present most commonly within the first year of biological treatment (60%), and often have a psoriasisform or pustular appearance. Especially in patients being treated with TNF-antagonists, paradoxical PsO may present palmoplantar with an acute onset of pustules. PPP is diagnosed in 36.3% of PSR in TNF-inhibitors, but plaques PsO (44.8%) and guttate PsO (11%) are also reported. Hair loss is also a common PSR in biological therapy, and presents with clinical and histopathological finding of alopecia areata and PSO capitis. There are also almost 50 cases of HS as PSR in the literature, with adalimumab and infliximab as the commonest causing agents. Notably, one-third of these patients had an additional PSR, with PsO and CD being the commonest. Autoimmune-bullous disorders such as pemphigus foliaceus, bullous pemphigoid or linear IgA dermatosis, as well as lupus-like syndromes, vasculitis and lichenoid skin eruptions have also been described. Commonly, PSR improve after discontinuation of the culprit agent, even within the same drug group. About one-third of patients with PSR need a discontinuation of the drug and these patients do not respond to topical treatments. The underlying mechanism is most likely a cytokine imbalance between TNF-α and type 1-interferons (IFN-α) favouring development of inflammatory plasmacytoid dendritic cells (pDCs) and increased type-1 IFN production. As a consequence of anti-TNF, type I IFNs are increased. Therefore, in PSR anti-TNF medication should be discontinued and a possible class switch should be considered.

Treatment
Treatment goals. With the introduction of a variety of new systemic therapeutic options over the last decade, treatment goals in inflammatory skin diseases and rheumatic disorders had to be reconsidered.

In PsO, the Psoriasis Area and Severity Index (PASI) and Body Surface Area (BSA) scores are the gold standards in measuring skin involvement. The PASI has a maximum score of 72 and is calculated on the basis of the percentage of affected skin in combination with its erythema, induration and scaling. The BSA represents the percentage of affected skin. The patient’s palm presents 1% of the body surface. Through therapies targeting TNF-α, IL-17/IL-23, PDE4 and JAK-STAT the total clearance of the skin, a PASI 100 and BSA < 1, may be achieved while the placebo effect on PsO is minimal.

Unfortunately, the treatment targets in joint involvement in current clinical trials are far from a total 100% clearance of inflammatory activity. This being said, primary endpoints with validated measurements of the American College of Rheumatology (ACR20, ACR50 or ACR70) responses in PsA and ASAS20 or ASAS40 in axSpA are the gold standard of musculoskeletal manifestation response measurement. In addition, the effects of placebo treatment are much higher for articular inflammation (up to 30%) than for skin inflammation. There is an ongoing discussion regarding whether articular diseases should be treated to target and what these targets are. While an elevated C-reactive protein is a SpA feature in its current classification and correlates with disease activity, in inflammatory skin conditions it represents disease severity only on severe skin conditions and might not reflect the need for treatment of moderate and mild disease.

In HS and PG, treatment goals have to consider that existing scarring will not be reversible. Pain,
were superior to corticosteroids. In 66.6% (n = 7) of patients. Notably, all of these were superior to corticosteroids.

In rare disorders like PG or CCD, clinical trials are rare and validated scoring systems lacking. A regular clinical picture along with the size of the lesion, together with a DLQI and a pain assessment on a visual analogue scale (VAS) should be monitored to evaluate efficacy.

TNF-α. TNF-α belongs to the first generation of biologicals. Current approved anti-TNF agents include adalimumab, certolizumab pegol, etanercept, golimumab and infliximab. Because of relatively long data accumulation, safety data for pregnancy for the use of certolizumab, etanercept and adalimumab are available.

While the response rates in PsA did not differ largely between adalimumab, certolizumab pegol, infliximab and etanercept, in PsO PASI, 90 responses ranged from 54% in infliximab, 30% in adalimumab, 48% in certolizumab and 24% in etanercept. Concerning skin involvement, response rates of etanercept are similar to those of methotrexate. A retrospective analysis of 52 patients suffering from PG showed complete remission with infliximab in 63.6% (n = 33), for adalimumab in 57.1% (n = 28), for etanercept in 71.4% (n = 7) and for ustekinumab in 66.6% (n = 9) of patients. Notably, all of these were superior to corticosteroids.

In HS, adalimumab is the only approved biologic and is recommended for moderate-to-severe HS that is unresponsive to antibiotics, with relatively good response rates. No significant difference comparing infliximab and placebo was observed for >50% improvement HiSCR, but the improvement rate of 25–50% was significantly higher for infliximab versus placebo. Etanercept does not benefit HS patients compared with placebo. There is limited data concerning the therapy of HS with golimumab or certolizumab, which was found to be ineffective in case series. To our knowledge, infliximab is the only biologic agent being assessed in a randomized controlled trial in PG showing superiority over placebo, whereas systemic prednisone and cyclosporine were assessed as classic immunosuppressants with no superiority of either drug. Recently, adalimumab was shown to be effective in an open-label phase III trial in PG (Figure 8). In therapy-resistant EN, anti-TNF-α therapy also shows a response rate of up to 80%. There is very limited data for the use of anti-TNF in ReA. In a retrospective study, skin and joint inflammation improved rapidly with biologicals but disease exacerbation followed cessation of the drug within the first 6 months.

In PsO, secukinumab showed PASI 90 scores of 76.6% and was superior in a head-to-head study against ustekinumab. In contrast to anti-TNF, the onset of efficacy is earlier in secukinumab. Ixekizumab also presents a fast onset with response rate superior to placebo at week 1 and a PASI 90 at 50% at week 8. Brodalumab has a similar response with PASI 90 at 70% at week 12 and showed, along with the others, no discernible loss of efficacy. Ixekizumab and secukinumab are also efficacious in nail and scalp psoriasis and approved for PsA. Interestingly, IL-17 blockade with secukinumab failed in patients with palmoplantar pustular PsO. Anti-IL-17 targets have been suggested to be associated with clinically relevant mucocutaneous candida infections as IL-17 pays an important role in defending candida infections. However, the risk seems to be limited. In addition, data are limited on the association of new-onset IBD and secukinumab, and recent insights loosen that association.

Secukinumab has been evaluated in clinical trials for moderate-to-severe HS and preliminary reports state a HiSCR of 67–70% at week 24 in cohort of TNF-naïve and TNF-refractory patients. Ixekizumab has been reported to be effective in HS in case studies. Other IL-17 antibodies such as secukinumab are currently in clinical trials for HS (Figure 9). Secukinumab and IL-23 and IL-23. Ustekinumab is the only approved biologic targeting the p40 unit shared...
### Figure 8. Efficacies targeting TNF-α in PsO, HS, PG, rSpA, nrSpA and PsA.

The size of the circle presents the level of evidence, the colour represents the level of efficacy in the indicated disease.\textsuperscript{124–138} As standards of therapeutic efficacies in PsO PASI90, in HS HiSCR, in SpA ASAS40 and in PsA ACR50 are used. The scheme is adapted from Eyerich et al.\textsuperscript{139}

| Treatment          | Psoriasis vulgaris | Hidradenitis suppurativa | Pyoderma gangrenosum | Radiographic axial Spondyloarthritis | Non-Radiographic axial Spondyloarthritis | Psoriatic arthritis |
|--------------------|--------------------|-------------------------|----------------------|--------------------------------------|-----------------------------------------|---------------------|
| Adalimumab         | EMA FDA            | EMA FDA                 |                      | EMA FDA                              | EMA FDA                                 | EMA FDA             |
| Elanercept         | EMA FDA            |                         |                      | EMA FDA                              | EMA FDA                                 | EMA FDA             |
| Infliximab         | EMA FDA            |                         |                      | EMA FDA                              | EMA FDA                                 | EMA FDA             |
| Golimumab          |                    |                         |                      | EMA FDA                              | EMA FDA                                 | EMA FDA             |
| Certolizumab pegol| EMA FDA            |                         |                      | EMA FDA                              | EMA FDA                                 | EMA FDA             |

EMA, European Medicines Agency; FDA, United States Federal Drug Administration; HS, hidradenitis suppurativa; nrSpA, non-radiographic axial SpA; PG, pyoderma gangrenosum; PsO, psoriasis; PsA, psoriatic arthritis; rSpA, radiographic axial SpA; SPA, spondyloarthritis; TNF-α, tumour necrosis factor alpha.

### Figure 9. Efficacies targeting IL-17 in PsO, HS, PG, rSpA, nrSpA and PsA.

The size of the circle presents the level of evidence, the colour represents the level of efficacy in the indicated disease.\textsuperscript{126,153–158} As standards of therapeutic efficacies in PsO PASI90, in HS HiSCR, in SpA ASAS40 and in PsA ACR50 are used. The scheme is adapted from Eyerich et al.\textsuperscript{139}

| Treatment          | Psoriasis vulgaris | Hidradenitis suppurativa | Pyoderma gangrenosum | Radiographic axial Spondyloarthritis | Non-Radiographic axial Spondyloarthritis | Psoriatic arthritis |
|--------------------|--------------------|-------------------------|----------------------|--------------------------------------|-----------------------------------------|---------------------|
| Secukinumab        | EMA FDA            |                         |                      | EMA FDA                              | EMA FDA                                 | EMA FDA             |
| Brodalumab         | EMA FDA            |                         |                      | EMA FDA                              | EMA FDA                                 | EMA FDA             |

EMA, European Medicines Agency; FDA, United States Federal Drug Administration; HS, hidradenitis suppurativa; IL-17, interleukin 17; nrSpA, non-radiographic axial SpA; PG, pyoderma gangrenosum; PsO, psoriasis; PsA, psoriatic arthritis; rSpA, radiographic axial SpA; SPA, spondyloarthritis.
by IL-12 and IL-23. For a more specific IL-23 blockade, the following antibodies bind to the specific p19 unit of IL-23: guselkumab, risankizumab and tildrakizumab. Ustekinumab’s response rates in PsO are 46% PASI 90,114,115 Risankizumab presented with 75.3% PASI 90 at week 16 and 82% at week 52. Impressively, the PASI 100 Score at week 52 was 60%, and patients showed a relatively long efficacy despite the cessation of the agent.159,160 However, it did not show efficacy in AS.161 Similarly, ustekinumab does not play a therapeutic role in axial SpA following negative phase III program results in axSpA, in contrast to joint inflammation in PsA with moderate clinical responses and beneficial effects of ustekinumab and guselkumab in axial involvement in PsA to some extent.161–163 To date, it is unclear why IL-23 targets do not improve axSpA in contrast to anti-IL-17 therapeutics.164 Tildrakizumab showed a PASI 90 response of 35% (week 12) and 59% (week 28) and guselkumab 72% PASI 90 (week 16) and 76% (week 48).165–167

Ustekinumab has been evaluated in a randomised controlled trial (RCT) showing clinical improvement of HS (HiSCR 47%, week 40) compared with placebo.105 In addition, risankizumab shows promising efficacy in case reports and is currently in phase II trials for CD and HS. In HS, guselkumab has been studied in case series. Systemic literature reviews suggest significant reduction in pain with improvements in lesions. RCT are currently recruiting with no published results yet.106

An increased expression of IL-23 and IL-17 in lesional PG skin led to numerous case reports of the efficacious use of ustekinumab, ixekizumab, risankizumab and brodalumab although clinical trials are missing (Figure 10).168,169

IL-1. Targeting IL-1 led to a revolutionary change in the treatment of auto-inflammatory skin diseases. Currently, canakinumab, rilonacept [not available in the European Union (EU)] and anakinra are approved anti-IL-1 drugs. Anakinra has been evaluated for PsO. As in PsA, anakinra
showed only a modest benefit in PsO, with partially worsening of skin involvement. In contrast to plaques PsO, IL-1 seems to play an important role in pustular PsO, and the results of a RTC are awaited.  

In syndromic PG, TNF-α-inhibitors and anti-IL-1 agents are most frequently used. Anakinra and canakinumab targeting IL-1 show limited efficacy in PG. In HS, anakinra is considered as third line in some countries. In a relatively small cohort, anakinra did initially show good efficacy, with HiSCR of 78% versus 30% in the placebo group after 3 months, but after 24 weeks no difference was found between the two groups. Evidence to support reproducible efficacy is limited. Canakinumab is used in Brazil because of unavailability of anakinra, but data show mixed results and RCTs are missing (Figure 11).  

IL-6. Since IL-6 plays a role in IL-23 induced differentiation of Th17 cells, targeting IL-6 led to new therapies in rheumatoid arthritis (RA), giant cell arteritis and is currently under evaluation for PsA. Targeting IL-6 may play an important role in palmoplantar pustulosis. Tocilizumab has been reported to be efficacious in TNF-triggered pustular PsO. On the other hand, several case reports of tocilizumab-induced psoriasis exist. (Figure 12)  

IL-36. IL-36 is a member of the IL-1 cytokine family that plays a central role in immunity and inflammation. It is overexpressed in PsO and RA patients in various stimuli, such as TNF-α, IL-17 lipopolysaccharides and double-stranded RNA. Comparing PsA and RA, IL-36 levels do not differ in the synovia but PsA shows a significant higher activation of IL-36 due to a lack of antagonist IL-36-RA and IL-38 in comparison with RA. Therefore, targeting IL-36 in PsA and pustular PsO seems to be a promising therapeutic approach and is currently being tested in clinical trials. Antagonizing IL-36 may also be beneficial in other neutrophil-dominated diseases.  

Janus tyrosine kinase inhibitors and small molecules. Janus tyrosine kinase inhibitors (JAKi) are small molecules and taken orally. To date, there are four members in the JAK family (JAK 1-3 and TYK2) with five approved agents: Baricitinib, filgotinib, tofacitinib, upadacitinib and ruxolitinib. These molecules are gaining increasing attention and are currently being tested in several dermatologic disorders.
efficacy in PsO, with PASI 75 responses of 55.2% (10 mg/day) and efficacy rates comparable with those of TNF- and IL-17 inhibitors in axSpA. Topical tofacitinib also improves PsO but is not approved. Baricitinib reached PASI 90 responses between 20% and 30% depending on the dose. JAKi may also be beneficial in palmoplantar PsO. So far, tofacitinib is the only JAKi approved for PsA but not for PsO. However, a large JAKi program studying the safety and efficacy of multiple JAKi for different PsO entities is ongoing.

There is very limited data for JAKi in HS. Tofacitinib shows good clinical results in two recalcitrant severe HS cases, not responding to targeted biologic therapies. Upadacitinib, topical ruxolitinib and INCB-054707 are currently under clinical investigation in HS (Figure 13).

Apremilast is a phosphodiesterase-4 inhibitor (PDE4) and inhibits the hydrolyzation of cAMP, leading to a decreased expression of the pro-inflammatory cytokines TNF-α, IFNγ and IL-12/ IL-23p40. It is approved for the treatment of moderate-to-severe plaque PsO, PsA and oral ulcers in Behçet’s disease, and did show beneficial effects in PsO in the difficult-to-treat sites nail, scalp and palmoplantar. In contrast, in AS, apremilast did not meet the primary endpoint in a phase III clinical trial with a higher ASAS40 in the placebo group [ClinicalTrials.gov identifier: NCT00944658]. Apremilast has been described as an effective treatment for PG, although RCT are lacking. PDE4 has recently been approved for Behçet’s disease, which belongs to the group of ulcerative neutrophilic disorders. Apremilast has also been evaluated in mild-to-moderate HS with improvement in disease activity (HiSCR 53.3%, week 16), pain, and quality of life in patients with less severe HS (Figure 14).

**Conclusion**

Skin manifestations in SpA are various. A knowledge of associated disorders and their therapeutic approaches are key to an interdisciplinary approach and optimal patient care. SpAs present in various clinical pictures and generally add an increased impact on quality of life since excessive scaling, discharge, itch and pain are common symptoms of skin inflammation. This review focussed on the most frequent comorbidities and their approved therapies. Most commonly, PsO manifests with numerous
Figure 13. Efficacies targeting JAK in PsO, HS, PG, rSpA, nrSpA and PsA. The size of the circle presents the level of evidence, the colour represents the level of efficacy in the indicated disease. As standards of therapeutic efficacies in PsO PASI90, in HS HiSCR, in SpA ASAS40 and in PsA ACR50 are used. The scheme is adapted from Eyerich et al. EMA, European Medicines Agency; FDA, United States Federal Drug Administration HS, hidradenitis suppurativa; JAK, Janus kinase; nrSpA, non-radiographic axial SPA; PG, pyoderma gangrenosum; PsO, psoriasis; PsA, psoriatic arthritis; rSpA, radiographic axial SpA; SPA, spondyloarthritis.

Figure 14. Efficacies of abatacept and apremilast in PsO, HS, PG, rSpA, nrSpA and PsA. The size of the circle presents the level of evidence, the colour represents the level of efficacy in the indicated disease. As standards of therapeutic efficacies in PsO PASI90, in HS HiSCR, in SpA ASAS40 and in PsA ACR50 are used. The scheme is adapted from Eyerich et al. EMA, European Medicines Agency; FDA, United States Federal Drug Administration HS, hidradenitis suppurativa; JAK, Janus kinase; nrSpA, non-radiographic axial SPA; PG, pyoderma gangrenosum; PsO, psoriasis; PsA, psoriatic arthritis; rSpA, radiographic axial SpA; SPA, spondyloarthritis.
clinical presentations. In SpA associated with IBD, another distinct group of skin manifestations such as PG, HS and EN are often seen. Thus, there have been reports of a variety of inflammatory skin responses such as erythema elevatum diutinum, discoid lupus and other vasculitides in patients with AS.229–231 Pathomechanistically, they all seem to share a common pathway, with dysregulation of classic inflammatory cytokines such as IL-1, IL-12/23, IL-17 and IL-23. Common genetic factors like HLA-B27 are also typical in these cohorts. Strikingly, IL-23 inhibitors show impressive response rates in PsO, with a high number of patients achieving complete remission and good efficacy in associated peripheral arthritis but are less effective in axial involvement. Hence, the efficacy of well-established targeted therapies differs greatly in associated morbidities. As of today, we need to find out why certain diseases respond differently, whether we can combine targeted therapies in order to achieve adequate responses in different entities without increasing the risk of side effects in our patients. Current clinical trials for several agents such as bimekizumab, filgotinib or beremekimab are likely to widen the number of effective therapeutic options for patients with inflammatory diseases.232,233

In order to achieve optimal patient care, individuals with complex inflammatory diseases need to be screened for these comorbidities in daily practice. In fact, knowledge of associated disorders, their pathomechanisms and therapeutic approaches may lead to different therapeutic strategies and may open doors for in-label therapies of new anti-inflammatory agents.

Conflict of interest statement
KM has received honoraria or travel expenses for lecture and research activities from Abbvie, Biogen, Celgene, Janssen-Cilag and UCB Pharma.

AS has received travel expenses from Janssen-Cilag and Celgene

DP has received grant/research support from AbbVie, Lilly, MSD, Novartis, and Pfizer; has been a consultant for AbbVie, Biocad, Gilead, GSK, Lilly, MSD, Novartis, Pfizer, Samsung and UCB; and served on the speakers bureau for AbbVie, BMS, Lilly, MSD, Novartis, Pfizer and UCB.

KG has received honoraria or travel expenses for lecture and research activities from Abbvie, Almirall, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Delenex, Eli Lilly, Galderma, Janssen-Cilag, Medac, MSD, Novartis, Pfizer and UCB Pharma.

Funding
The authors received no financial support for the research, authorship, and/or publication of this article.

ORCID iDs
Katharina Meier https://orcid.org/0000-0002-4687-3195
Denis Poddubnyy https://orcid.org/0000-0002-4537-6015

References
1. Braun J, Bollow M, Remlinger G, et al. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. *Arthritis Rheum* 1998; 41: 58–67.

2. Rudwaleit M, van der Heijde D, Landewé R, et al. The development of assessment of spondyloarthritis international society classification criteria for axial spondyloarthritis (part II): validation and final selection. *Ann Rheum Dis* 2009; 68: 777–783.

3. Proft F and Poddubnyy D. Ankylosing spondylitis and axial spondyloarthritis: recent insights and impact of new classification criteria. *Ther Adv Musculoskelet Dis* 2018; 10: 129–139.

4. Ghoreschi K, Laurence A, Yang X-P, et al. Generation of pathogenic T_{h}17 cells in the absence of TGF-β signalling. *Nature* 2010; 467: 967–971.

5. Jethwa H and Bowness P. The interleukin (IL)-23/IL-17 axis in ankylosing spondylitis: new advances and potentials for treatment. *Clin Exp Immunol* 2016; 183: 30–36.

6. Dougados M and Baeten D. Spondyloarthritis. *Lancet* 2011; 377: 2127–2137.

7. Sherlock JP, Joyce-Shaikh B, Turner SP, et al. IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4 CD8+ entheseal resident T cells. *Nat Med* 2012; 18: 1069–1076.

8. Sabat R, Wolk K, Loyal L, et al. T cell pathology in skin inflammation. *Semin Immunopathol* 2019; 41: 359–377.

9. Naldi L. Epidemiology of psoriasis. *Curr Drug Targets Inflamm Allergy* 2004; 3: 121–128.

10. Parisi R, Symmons DP, Griffiths CE, et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. *J Invest Dermatol* 2013; 133: 377–385.
11. Ritchlin CT, Colbert RA and Gladman DD. Psoriatic arthritis. *N Engl J Med* 2017; 376: 957–970.

12. Scher JU, Ogdie A, Merola JF, et al. Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition. *Nat Rev Rheumatol* 2019; 15: 153–166.

13. Tillett W, Charlton R, Nightingale A, et al. Interval between onset of psoriasis and psoriatic arthritis comparing the UK Clinical Practice Research Datalink with a hospital-based cohort. *Rheumatology (Oxford)* 2017; 56: 2109–2113.

14. Siegel EL, Orbai A-M and Ritchlin CT. Psoriasis. *Br J Dermatol* 2017; 176: 731–739.

15. Okhovat JP, Ogdie A, Reddy SM, et al. Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network Consortium (PPACMAN) survey: benefits and challenges of combined rheumatology-dermatology clinics. *J Rheumatol* 2017; 44: 693–694.

16. Roure F, Elhai M, Burki V, et al. Prevalence and clinical characteristics of psoriasis in spondyloarthritis: a descriptive analysis of 275 patients. *Clin Exp Rheumatol* 2016; 34: 82–87.

17. Jadon DR, Sengupta R, Nightingale A, et al. Axial disease in psoriatic arthritis study: defining the clinical and radiographic phenotype of psoriatic spondyloarthritis. *Ann Rheum Dis* 2017; 76: 701–707.

18. Cunha JS, Qureshi AA and Reginato AM. Nail enthesal ultrasound in psoriasis and psoriatic arthritis: a report from the 2016 GRAPPA annual meeting. *J Rheumatol* 2017; 44: 688–690.

19. Wilson FC, Icen M, Crowson CS, et al. Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study. *Arthritis Rheum* 2009; 61: 233–239.

20. Rouzaud M, Sevrain M, Villani AP, et al. Is there a psoriasis skin phenotype associated with psoriatic arthritis? Systematic literature review. *J Eur Acad Dermatol Venereol* 2014; 28(Suppl. 5): 17–26.

21. Bochncke WH and Schon MP. Psoriasis. *Lancet* 2015; 386: 983–994.

22. Bruck J, Dringen R, Amasuno A, et al. A review of the mechanisms of action of dimethylfumarate in the treatment of psoriasis. *Exp Dermatol* 2018; 27: 611–624.

23. Martin BA, Chalmers RJ and Telfer NR. How great is the risk of further psoriasis following a single episode of acute guttate psoriasis? *Arch Dermatol* 1996; 132: 717–718.

24. Durham GA and Morgan JK. A 7-year follow-up study of ninety patients with psoriasis. *Br J Dermatol* 1974; 91: 7–11.

25. Ko HC, Jwa SW, Song M, et al. Clinical course of guttate psoriasis: long-term follow-up study. *J Dermatol* 2010; 37: 894–899.

26. Naldi L, Peli L, Parazzini F, et al.; Psoriasis Study Group of the Italian Group for Epidemiological Research in Dermatology. Family history of psoriasis, stressful life events, and recent infectious disease are risk factors for a first episode of acute guttate psoriasis: results of a case-control study. *J Am Acad Dermatol* 2001; 44: 433–438.

27. Aydin SZ, Castillo-Gallego C, Ash ZR, et al. Ultrasonographic assessment of nail in psoriatic disease shows a link between onychopathy and distal interphalangeal joint extensor tendon enthesisopathy. *Dermatology* 2012; 225: 231–235.

28. Castellanos-González M, Joven BE, Sánchez J, et al. Nagelbefeinn kann bei Patienten mit Psoriasis auf eine Enthesiopathie hinweisen. *J Dtsch Dermatol Ges* 2016; 14: 1102–1108.

29. Bardazzi F, Lambertini M, Chessa MA, et al. Nail involvement as a negative prognostic factor in biological therapy for psoriasis: a retrospective study. *J Eur Acad Dermatol Venereol* 2017; 31: 843–846.

30. Jiarchvithsan MM, Sasseville D, Vender RB, et al. Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy. *J Am Acad Dermatol* 2007; 57: 1–27.

31. Tzung TY, Chen CY, Yang CY, et al. Calcipotriol used as monotherapy or combination therapy with betamethasone dipropionate in the treatment of nail psoriasis. *Acta Derm Venereol* 2008; 88: 279–280.

32. Marrakchi S, Guigue P, Renshaw BR, et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. *N Engl J Med* 2011; 365: 620–628.

33. Jordan CT, Cao L, Roberson ED, et al. PSORS2 is due to mutations in CARD14. *Am J Hum Genet* 2012; 90: 784–795.

34. Setta-Kaffetzzi N, Navarini AA, Patel VM, et al. Rare pathogenic variants in IL36RN underlie a spectrum of psoriasis-associated pustular phenotypes. *J Invest Dermatol* 2013; 133: 1366–1369.

35. Korber A, Mossner R, Renner R, et al. Mutations in IL36RN in patients with...
36. Johnston A, Xing X, Wolterink L, et al. IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis. *J Allergy Clin Immunol* 2017; 85: 20–26.

37. Bissonnette R, Fuentes-Duculan J, Mashiko S, *et al.* Palmpoplantar pustular psoriasis (PPPp) is characterized by activation of the IL-17A pathway. *J Dermatol Sci* 2017; 85: 20–26.

38. Navarini AA, Burden AD, Capon F, *et al.* European consensus statement on phenotypes of pustular psoriasis. *J Eur Acad Dermatol Venereol* 2017; 31: 1792–1799.

39. Kromer C, Loewe E, Schaarschmidt M-L, *et al.* Treatment of acrodermatitis continua of Hallopeau: a case series of 39 patients. *J Dermatol* 2017; 44: 711–716.

40. Herberger K, Dissemond J, Hohaus K, *et al.* Extraintestinal diagnoses in ulcerative colitis: an epidemiological study. *Am J Gastroenterol* 2003; 9: 603–606.

41. Lakatos L, Pandur T, David G, *et al.* Association of extraintestinal manifestations of inflammatory bowel disease in a province of western Hungary with disease phenotype: results of a 25-year follow-up study. *World J Gastroenterol* 2003; 9: 2300–2307.

42. Jumani L, Kataria D, Ahmed MU, *et al.* The spectrum of extra-intestinal manifestation of Crohn’s disease. *Cureus* 2020; 12: e6928.

43. Vavricka SR, Brun L, Ballabeni P, *et al.* Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. *Am J Gastroenterol* 2011; 106: 110–119.

44. Binus AM, Qureshi AA, Li VW, *et al.* Pyoderma gangrenosum: a retrospective review of patient characteristics, comorbidities and therapy in 103 patients. *Br J Dermatol* 2011; 165: 1244–1250.

45. Langan SM, Groves RW, Card TR, *et al.* Incidence, mortality, and disease associations of pyoderma gangrenosum in the United Kingdom: a retrospective cohort study. *J Invest Dermatol* 2012; 132: 2166–2170.

46. Caproni M, Antiga E, Volpi W, *et al.* The Treg/Th17 cell ratio is reduced in the skin lesions of patients with pyoderma gangrenosum. *Br J Dermatol* 2015; 173: 275–278.

47. Marzano AV, Fanoni D, Antiga E, *et al.* Expression of cytokines, chemokines and other effector molecules in two prototypic autoinflammatory skin diseases, pyoderma gangrenosum and Sweet’s syndrome. *Clin Exp Immunol* 2014; 178: 48–56.

48. Ashchyran HJ, Butler DC, Nelson CA, *et al.* The association of age with clinical presentation and comorbidities of pyoderma gangrenosum. *JAMA Dermatol* 2018; 174: e35–e36.

49. Freeman HJ. Erythema nodosum and pyoderma gangrenosum-a retrospective analysis. *Br J Dermatol* 2016; 175: 882–891.

50. Xia FD, Liu K, Lockwood S, *et al.* Risk of developing pyoderma gangrenosum after procedures in patients with a known history of pyoderma gangrenosum-a retrospective analysis. *J Am Acad Dermatol* 2018; 78: 310–314.e1.

51. Herberger K, Dissemont J, Hohaus K, *et al.* Treatment of pyoderma gangrenosum: retrospective multicentre analysis of 121 patients. *Br J Dermatol* 2016; 175: 1070–1072.

52. Lakatos PL, Lakatos L, Kiss LS, *et al.* Treatment of extraintestinal manifestations in inflammatory bowel disease. *Digestion* 2012; 86(Suppl. 1): 28–35.

53. Bjorn-Mortensen K, Ladefoged K, Simonsen J, *et al.* Erythema nodosum and the risk of tuberculosis in a high incidence setting. *Int J Circumpolar Health* 2016; 75: 32666.
60. Teixeira M, Machado S, Lago P, et al. Cutaneous Crohn’s disease. *Int J Dermatol* 2006; 45: 1074–1076.

61. Parks AG, Morson BC and Pegum JS. Crohn’s disease with cutaneous involvement. *Proc R Soc Med* 1965; 58: 241–242.

62. Mountain JC. Cutaneous ulceration in Crohn’s disease. *Gut* 1970; 11: 18–26.

63. Matusiak L, Bieniek A and Szepietowski JC. Psychophysical aspects of hidradenitis suppurativa. *Acta Derm Venereol* 2010; 90: 264–268.

64. Revuz JE, Canou-Cohen F, Wolkenstein P, et al. Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies. *J Am Acad Dermatol* 2008; 59: 596–601.

65. Garg A, Lavian J, Lin G, et al. Incidence of hidradenitis suppurativa in the United States: a sex- and age-adjusted population analysis. *J Am Acad Dermatol* 2017; 77: 118–122.

66. Kokolakis G, Wolk K, Schneider-Burrus S, et al. Delayed diagnosis of hidradenitis suppurativa and its effect on patients and healthcare system. *Dermatology* 2020; 236: 421–430.

67. Garg A, Hundal J and Strunk A. Overall and subgroup prevalence of Crohn disease among patients with hidradenitis suppurativa: a population-based analysis in the United States. *JAMA Dermatol* 2018; 154: 814–818.

68. Rumberger BE, Boarder EL, Owens SL, et al. Transcriptomic analysis of hidradenitis suppurativa skin suggests roles for multiple inflammatory pathways in disease pathogenesis. *Inflamm Res* 2020; 69: 967–973.

69. Marzano AV, Menicanti C, Crosti C, et al. Neutrophilic dermatoses and inflammatory bowel diseases. *G Ital Dermatol Venereol* 2013; 148: 185–196.

70. van der Zee HH, de Ruiter L, van den Broecke DG, et al. Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-α and IL-1β. *Br J Dermatol* 2011; 164: 1292–1298.

71. Moran B, Sweeney CM, Hughes R, et al. Hidradenitis suppurativa is characterized by dysregulation of the Th17: Treg cell axis, which is corrected by anti-TNF therapy. *J Invest Dermatol* 2017; 137: 2389–2395.

72. Richette P, Molto A, Viguier M, et al. Hidradenitis suppurativa associated with spondyloarthritis -- results from a multicenter national prospective study. *J Rheumatol* 2014; 41: 490–494.

73. Rondags A, Arends S, Wink FR, et al. High prevalence of hidradenitis suppurativa symptoms in axial spondyloarthritis patients: a possible new extra-articular manifestation. *Semin Arthritis Rheum* 2019; 48: 611–617.

74. Faucier M, Reguiai Z, Barbe C, et al. Association between hidradenitis suppurativa and spondyloarthritis. *Joint Bone Spine* 2018; 85: 593–597.

75. Lee JH, Kwon HS, Jung HM, et al. Prevalence and comorbidities associated with hidradenitis suppurativa in Korea: a nationwide population-based study. *J Eur Acad Dermatol Venereol* 2018; 32: 1784–1790.

76. Hendricks AJ, Hsiao JL, Lowes MA, et al. A comparison of international management guidelines for hidradenitis suppurativa. *Dermatology*. Epub ahead of print 23 October 2019. DOI: 10.1159/000503605.

77. Alkan A, Sayed C, Alavi A, et al. North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: part I: diagnosis, evaluation, and the use of complementary and procedural management. *J Am Acad Dermatol* 2019; 81: 76–90.

78. Ingram JR, Collier F, Brown D, et al. British Association of Dermatologists guidelines for the management of hidradenitis suppurativa (acne inversa) 2018. *Br J Dermatol* 2019; 180: 1009–1017.

79. Gulliver W, Zouboulis CC, Prens E, et al. Evidence-based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the European guidelines for hidradenitis suppurativa. *Rev Endocr Metab Disord* 2016; 17: 343–351.

80. Albrecht J, Barbaric J and Nast A. Rifampicin alone may be enough: is it time to abandon the classic oral clindamycin-rifampicin combination for hidradenitis suppurativa? *Br J Dermatol* 2019; 180: 949–950.

81. Feltkamp TE. Factors involved in the pathogenesis of HLA-B27 associated arthritis. *Scand J Rheumatol Suppl* 1995; 101: 213–217.

82. Inman RD, Whittum-Hudson JA, Schumacher HR, et al. Chlamydia and associated arthritis. *Curr Opin Rheumatol* 2000; 12: 254–262.

83. Gérard HC, Branigan PJ, Schumacher HR Jr, et al. Synovial Chlamydia trachomatis in patients
with reactive arthritis/Reiter’s syndrome are viable but show aberrant gene expression. *J Rheumatol* 1998; 25: 734–742.

84. Granfors K, Jalkanen S, Lindberg AA, *et al.* Salmonella lipopolysaccharide in synovial cells from patients with reactive arthritis. *Lancet* 1990; 335: 685–688.

85. Porter CK, Choi D and Riddle MS. Pathogen-specific risk of reactive arthritis from bacterial causes of foodborne illness. *J Rheumatol* 2013; 40: 712–714.

86. Curry JA, Riddle MS, Gormley RP, *et al.* The epidemiology of infectious gastroenteritis related reactive arthritis in U.S. military personnel: a case-control study. *BMC Infect Dis* 2010; 10: 266.

87. Chua-Aguilera CJ, Moller B and Yawalkar, *et al.* Salmonella lipopolysaccharide in synovial cells from patients with reactive arthritis. *Lancet* 1990; 335: 685–688.

88. Schneider JM, Matthews JH and Graham BS. *J Rheumatol* 2017; 40: 712–714.

89. Lucchino B, Spinelli FR, Perricone C, *et al.* Combination antibiotics as a treatment for chronic Chlamydia-induced reactive arthritis: a double-blind, placebo-controlled, prospective trial. *Arthritis Rheum* 2010; 62: 1298–1307.

90. Gupta V, Mohta P, Sharma VK, *et al.* A retrospective case series of 12 patients with chronic reactive arthritis with emphasis on treatment outcome with biologics. *Indian J Dermatol Venereol Leprol* Epub ahead of print 11 July 2019. DOI: 10.4103/ijdvl.IJDVL_519_18.

91. Benham H, Rehaume LM, Hasnain SZ, *et al.* interleukin-23 mediates the intestinal response to microbial β-1,3-glucan and the development of sponylaroarthritides pathology in SKG mice. *Arthritis Rheumatol* 2014; 66: 1755–1767.

92. Gawdzik A, Ponikowska M, Jankowska-Konsur A, *et al.* Paradoxical skin reaction to certolizumab, an overlap of pyoderma gangrenosum and psoriasis in a young woman treated for ankylosing spondylitis: case report with literature review. *Dermatol Ther (Heidelberg)* 2020; 10: 869–879.

93. Hayakawa M, Izumi K, Higashida-Konishi M, *et al.* Tocilizumab-induced psoriasis-like eruption resolved by shortening the dose interval in a patient with rheumatoid arthritis: a case-based review. *Rheumatol Int* 2019; 39: 161–166.

94. Brown G, Wang E, Leon A, *et al.* Tumor necrosis factor-α inhibitor-induced psoriasis: systematic review of clinical features, histopathological findings, and management experience. *J Am Acad Dermatol* 2017; 76: 334–341.

95. Brown G, Wang E, Leon A, *et al.* Tumor necrosis factor-α inhibitor-induced psoriasis: systematic review of clinical features, histopathological findings, and management experience. *J Am Acad Dermatol* 2017; 76: 334–341.

96. Aragon-Miguel R, Calleja-Algarra A, Vico-Alonso C, *et al.* Psoriatic alopecia-like paradoxical reaction to certolizumab pegol. *Int J Dermatol* 2019; 58: e118–e120.

97. Doyle LA, Sperling LC, Baksh S, *et al.* Psoriatic alopecia/alopexia areata-like reactions secondary to anti-tumor necrosis factor-α therapy: a novel cause of noncicatricial alopecia. *Am J Dermatopathol* 2011; 33: 161–166.

98. Toda-Brito H, Lopes L, Soares-Almeida L, *et al.* Adalimumab-induced psoriatic alopecia/alopexia areata-like reaction in a patient with Crohn’s disease. *Dermatol Online J* 2015; 21: 13030/qt79j1d2y.

99. Shaharir SS, Jamil A, Chua SH, *et al.* A case paradoxical hidradenitis suppurativa (HS) with janus kinase inhibitor, literature review and pooled analysis of biological agent-induced HS. *Dermatol Ther.* Epub ahead of print 16 July 2020. DOI: 10.1111/dth.14021.

100. Capusan TM, Herrero-Moyano M, Martinez-Mera CR, *et al.* Oral lichenoid reaction in a psoriatic patient treated with secukinumab: a drug-related rather than a class-related adverse event? *JAAD Case Rep* 2018; 4: 521–523.

101. Hernandez MV, Sanmarti R, Canete JD, *et al.* Cutaneous adverse events during treatment of chronic inflammatory rheumatic conditions with tumor necrosis factor antagonists: study using the Spanish registry of adverse events of biological therapies in rheumatic diseases. *Arthritis Care Res (Hoboken)* 2013; 65: 2024–2031.

102. Marzano AV, Borghi A, Meroni PL, *et al.* Immune-mediated inflammatory reactions and tumors as skin side effects of inflammatory bowel disease therapy. *Autoimmunity* 2014; 47: 146–153.

103. Conrad C, Di Domizio J, Mylonas A, *et al.* TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis. *Nat Commun* 2018; 9: 25.

104. Gacovic S, De Simone C, Genovese G, *et al.* Paradoxical skin reactions to biologics in patients with rheumatologic disorders. *Front Pharmacol* 2019; 10: 282.

105. Armstrong AW, Siegel MP, Bagel J, *et al.* From the Medical Board of the National Psoriasis Foundation: treatment targets for
plaque psoriasis. *J Am Acad Dermatol* 2017; 76: 290–298.

106. Papp K, Reich K, Leonardi CL, *et al.* Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). *J Am Acad Dermatol* 2015; 73: 37–49.

107. Bai F, Li GG, Liu Q, *et al.* Short-term efficacy and safety of IL-17, IL-12/23, and IL-23 inhibitors brodalumab, secukinumab, ixekizumab, ustekinumab, guselkumab, tilorakizumab, and risankizumab for the treatment of moderate to severe plaque psoriasis: a systematic review and network meta-analysis of randomized controlled trials. *J Immunol Res* 2019; 2019: 2546161.

108. Carrera CG, Dapavo P, Malagoli P, *et al.* PACE study: real-life Psoriasis Area and Severity Index (PASI) 100 response with biological agents in moderate-severe psoriasis. *Dermatolog Treat* 2018; 29: 481–486.

109. Smolen JS, Schols M, Braun J, *et al.* Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. *Ann Rheum Dis* 2018; 77: 3–17.

110. Beggi S, Lajevardi V and Abedini R. C-reactive protein in psoriasis: a review of the literature. *J Eur Acad Dermatol Venereol* 2014; 28: 700–711.

111. Cloose MEB, Scheuere AE, Chambers C, *et al.* Pregnancy outcomes after exposure to certolizumab pegol: updated results from a pharmacovigilance safety database. *Arthritis Rheumatol* 2018; 70: 1399–1407.

112. Burmester GR, Landewe R, Genovese MC, *et al.* Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis. *Ann Rheum Dis* 2017; 76: 414–417.

113. Broms G, Kieler H, Ekborn A, *et al.* Anti-TNF treatment during pregnancy and birth outcomes: a population-based study from Denmark, Finland, and Sweden. *Pharmacoepidemiol Drug Saf* 2020; 29: 316–327.

114. Reich K, Burden AD, Eaton JN, *et al.* Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials. *Br J Dermatol* 2012; 166: 179–188.

115. Gottlieb AB, Blauvelt A, Thaci D, *et al.* Certolizumab pegol for the treatment of chronic plaque psoriasis: results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2). *J Am Acad Dermatol* 2018; 79: 302–314.e6.

116. Egeberg A, Ottosen MB, Gniadecki R, *et al.* Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis. *Br J Dermatol* 2018; 178: 509–519.

117. Herberger K, Dissemond J, Brüggestrat S, *et al.* Biologics and immunoglobulins in the treatment of pyoderma gangrenosum - analysis of 52 patients. *J Dtsch Dermatol Ges* 2019; 17: 32–41.

118. Kimball AB, Okun MM, Williams DA, *et al.* Two phase 3 trials of adalimumab for hidradenitis suppurativa. *N Engl J Med* 2016; 375: 422–434.

119. Grant A, Gonzalez T, Montgomery MO, *et al.* Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. *J Am Acad Dermatol* 2010; 62: 205–217.

120. Prussick L, Rothstein B, Joshupina D, *et al.* Open-label, investigator-initiated, single-site exploratory trial evaluating secukinumab, an anti-interleukin-17A monoclonal antibody, for patients with moderate-to-severe hidradenitis suppurativa. *Br J Dermatol* 2019; 181: 609–611.

121. Brooklyn TN, Dunnill MG, Shetty A, *et al.* Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. *Gut* 2006; 55: 505–509.

122. Ormerod AD, Thomas KS, Craig FE, *et al.* Comparison of the two most commonly used treatments for pyoderma gangrenosum: results of the STOP GAP randomised controlled trial. *BMJ* 2015; 350: h2958.

123. Yamasaki K, Yamanaka K, Zhao Y, *et al.* Adalimumab in Japanese patients with active ulcers of pyoderma gangrenosum: twenty-six-week phase 3 open-label study. *J Dermatol* Epub ahead of print 17 August 2020. DOI: 10.1111/1346-8138.15533.

124. Mounach A and El Maghraoui A. Efficacy and safety of adalimumab in ankylosing spondylitis. *Open Access Rheumatol* 2014; 6: 83–90.

125. Sieper J, van der Heijde D, Dougados M, *et al.* Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). *Ann Rheum Dis* 2013; 72: 815–822.

126. Mease PJ, Smolen JS, Behrens F, *et al.* A head-to-head comparison of the efficacy and safety
of ixekizumab and adalimumab in biological-naive patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. *Ann Rheum Dis* 2020; 79: 123–131.

127. Dougados M, Wood E, Combe B, et al. Evaluation of the nonsteroidal anti-inflammatory drug-sparing effect of etanercept in axial spondyloarthropathy: results of the multicenter, randomized, double-blind, placebo-controlled SPARSE study. *Arthritis Res Ther* 2014; 16: 481.

128. Maksymowych WP, Dougados M, van der Heijde D, et al. Clinical and MRI responses to etanercept in early non-radiographic axial spondyloarthritis: 48-week results from the EMBARK study. *Ann Rheum Dis* 2016; 75: 1328–1335.

129. Mease PJ, Gladman DD, Collier DH, et al. Etanercept and methotrexate as monotherapy or in combination for psoriatic arthritis: primary results from a randomized, controlled phase III trial. *Arthritis Rheumatol* 2019; 71: 1112–1124.

130. Park W, Yoo DH, Jaworski J, et al. Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study. *Arthritis Res Ther* 2016; 18: 25.

131. Lin Z, Liao Z, Huang J, et al. Predictive factors of clinical response of infliximab therapy in active nonradiographic axial spondyloarthritis patients. *Biomed Res Int* 2015; 2015: 876040.

132. Antoni C, Krueger GG, de Vlam K, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. *Ann Rheum Dis* 2005; 64: 1150–1157.

133. Deodhar A, Braun J, Inman RD, et al. Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study. *Ann Rheum Dis* 2015; 74: 757–761.

134. van der Heijde D, Joshi A, Pangan AL, et al. ASAS40 and ASDAS clinical responses in the ABILITY-1 clinical trial translate to meaningful improvements in physical function, health-related quality of life and work productivity in patients with non-radiographic axial spondyloarthritis. *Rheumatology (Oxford)* 2016; 55: 80–88.

135. Kavanaugh A, McInnes IB, Mease PJ, et al. Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study. *Ann Rheum Dis* 2013; 72: 1777–1785.

136. van der Heijde D, Dougados M, Landewé R, et al. Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA. *Rheumatology (Oxford)* 2017; 56: 1498–1509.

137. Deodhar A, Gensler LS, Kay J, et al. A fifty-two-week, randomized, placebo-controlled trial of certolizumab pegol in nonradiographic axial spondyloarthritis. *Arthritis Rheumatol* 2019; 71: 1101–1111.

138. Mease PJ, Fleischmann R, Deodhar AA, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). *Ann Rheum Dis* 2014; 73: 48–55.

139. Eyerich K and Eyerich S. Immune response patterns in non-communicable inflammatory skin diseases. *J Eur Acad Dermatol Venereol* 2018; 32: 692–703.

140. Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis—results of two phase 3 trials. *N Engl J Med* 2014; 371: 326–338.

141. Bagel J, Nia J, Hashim PW, et al. Secukinumab is superior to ustekinumab in clearing skin in patients with moderate to severe plaque psoriasis (16-week CLARITY results). *Dermatol Ther (Heidelb)* 2018; 8: 571–579.

142. Deodhar A, Mease PJ, McInnes IB, et al. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data. *Arthritis Res Ther* 2019; 21: 111.

143. Foulkes AC and Warren RB. Brodalumab in psoriasis: evidence to date and clinical potential. *Drugs Context* 2019; 8: 212570.

144. Bagel J, Duffin KC, Moore A, et al. The effect of secukinumab on moderate-to-severe scalp psoriasis: results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study. *J Am Acad Dermatol* 2017; 77: 667–674.

145. Reich K, Sullivan J, Arenberger P, et al. Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial. *Br J Dermatol* 2019; 181: 954–966.
146. Langley RG, Rich P, Menter A, et al. Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasis. J Eur Acad Dermatol Venereol 2015; 29: 1763–1770.

147. Mrowietz U, Bachelez H, Burden AD, et al. Secukinumab for moderate-to-severe palmoplantar pustular psoriasis: results of the 2PRECISE study. J Am Acad Dermatol 2019; 80: 1344–1352.

148. Saunte DM, Mrowietz U, Puig L, et al. Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management. Br J Dermatol 2017; 177: 47–62.

149. Schreiber S, Colombel JF, Feagan BG, et al. Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankyllosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials. Ann Rheum Dis 2019; 78: 473–479.

150. Korzenik J, Larsen MD, Nielsen J, et al. Increased risk of developing Crohn’s disease or ulcerative colitis in 17 018 patients while under treatment with anti-TNFα agents, particularly etanercept, for autoimmune diseases other than inflammatory bowel disease. Aliment Pharmacol Ther 2019; 50: 289–294.

151. Casseres RG, Prussick L, Zancanaro P, et al. Secukinumab in the treatment of moderate to severe hidradenitis suppurativa: results of an open-label trial. J Am Acad Dermatol 2020; 82: 1524–1526.

152. Megna M, Ruggiero A, Di Guida A, et al. Ixekizumab: an efficacious treatment for both psoriasis and hidradenitis suppurativa. Dermatol Ther 2020; 33: e13756.

153. Brodalumab in psoriatic arthritis (PsA): 24-week results from the phase III AMVISON-1 and -2 trials. J Am Acad Dermatol 2019; 81: AB28.

154. Pavelka K, Kvitíz A, Dokoupilova E, et al. Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3. Arthritis Res Ther 2017; 19: 285.

155. Deodhar A, Blanco R, Dokoupilova E, et al. Secukinumab improves signs and symptoms of non-radiographic axial spondyloarthritis: primary results of a randomized controlled phase III study. Arthritis Rheumatol. Epub ahead of print 7 August 2020. DOI: 10.1002/art.41477.

156. Nash P, Mease PJ, McInnes IB, et al. Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3). Arthritis Res Ther 2018; 20: 47.

157. van der Heijde D, Cheng-Chung Wei J, Dougados M, et al. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. Lancet 2018; 392: 2441–2451.

158. Deodhar A, van der Heijde D, Gensler LS, et al. Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial. Lancet 2020; 395: 53–64.

159. Gordon KB, Strober B, Lebwohl M, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet 2018; 392: 650–661.

160. Papp KA, Blauvelt A, Bukhalo M, et al. Risankizumab versus Ustekinumab for moderate-to-severe plaque psoriasis. N Engl J Med 2017; 376: 1551–1560.

161. Baeten D, Ostergaard M, Wei JC, et al. Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study. Ann Rheum Dis 2018; 77: 1295–1302.

162. Deodhar A, Gensler LS, Sieper J, et al. Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis. Arthritis Rheumatol 2019; 71: 258–270.

163. Mease PJ, Rahman P, Gottlieb AB, et al. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet 2020; 395: 1126–1136.

164. Sieper J, Podubny D and Miossec P. The IL-23–IL-17 pathway as a therapeutic target in axial spondyloarthritis. Nat Rev Rheumatol 2019; 15: 747–757.

165. Papp K, Thaci D, Reich K, et al. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase Ib randomized placebo-controlled trial. Br J Dermatol 2015; 173: 930–939.
166. Reich K, Papp KA, Blauvelt A, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. *Lancet* 2017; 390: 276–288.

167. Blauvelt A, Papp KA, Griffiths CE, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. *J Am Acad Dermatol* 2017; 76: 405–417.

168. Guenova E, Teske A, Fehrenbacher B, et al. Interleukin 23 expression in pyoderma gangrenosum and targeted therapy with ustekinumab. *Arch Dermatol* 2011; 147: 1203–1205.

169. Low ZM and Mar A. Treatment of severe recalcitrant pyoderma gangrenosum with ustekinumab. *Australas J Dermatol* 2018; 59: 131–134.

170. Mease PJ, Chohan S, Fructuoso F, et al. Efficacy and safety of tildrakizumab, a high-affinity anti-interleukin-23p19 monoclonal antibody, in patients with active psoriatic arthritis in a randomized, double-blind, placebo-controlled, multiple-dose, phase 2B study. *Ann Rheum Dis* 2020; 79: 145–146.

171. 2017 ACR/ARHP annual meeting abstract supplement. *Arthritis Rheumatol* 2017; 69(Suppl. 10): 1–4426.

172. Strober B, Menter A, Leonardi C, et al. Efficacy of risankizumab in patients with moderate-to-severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa-1 and UltIMMa-2 studies. *J Eur Acad Dermatol Venereol*. Epub ahead of print 22 April 2020. DOI: 10.1111/jdv.16521.

173. Jung N, Hellmann M, Hoheisel R, et al. An open-label pilot study of the efficacy and safety of anakinra in patients with psoriatic arthritis refractory to or intolerant of methotrexate (MTX). *Clin Rheumatol* 2010; 29: 1169–1173.

174. Cornelius V, Wilson R, Cro S, et al. A small population, randomised, placebo-controlled trial to determine the efficacy of anakinra in the treatment of pustular psoriasis: study protocol for the APRICOT trial. *Trials* 2018; 19: 465.

175. Brenner M, Ruzicka T, Plewig G, et al. Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra. *Br J Dermatol* 2009; 161: 1199–1201.

176. Sun NZ, Ro T, Jolly P, et al. Non-response to interleukin-1 antagonist canakinumab in two patients with refractory pyoderma gangrenosum and hidradenitis suppurativa. *J Clin Aesthet Dermatol* 2017; 10: 36–38.

177. Tzanetakou V, Kanni T, Giatrakou S, et al. Safety and efficacy of anakinra in severe hidradenitis suppurativa: a randomised clinical trial. *JAMA Dermatol* 2016; 152: 52–59.

178. Beynon C, Chin MF, Hunashally P, et al. Successful treatment of autoimmune disease-associated pyoderma gangrenosum with the IL-1 receptor antagonist anakinra: a case series of 3 patients. *J Clin Rheumatol* 2017; 23: 181–183.

179. Haibel H, Rudwaleit M, Listing J, et al. Open label trial of anakinra in active ankylosing spondylitis over 24 weeks. *Ann Rheum Dis* 2005; 64: 296–298.

180. Jaeger T, Andres C, Grosber M, et al. Pyoderma gangrenosum and concomitant hidradenitis suppurativa—rapid response to canakinumab (anti-IL-1β). *Eur J Dermatol* 2013; 23: 408–410.

181. Tekin B, Salman A and Ergun T. Hidradenitis suppurativa unresponsive to canakinumab treatment: a case report. *Indian J Dermatol Venereol Leprol* 2017; 83: 615–617.

182. Tsai YC and Tsai TF. Anti-interleukin and interleukin therapies for psoriasis: current evidence and clinical usefulness. *Ther Adv Musculoskelet Dis* 2017; 9: 277–294.

183. Baganz L, Listing J, Kekow J, et al. Different risk profiles of biologic agents for new-onset psoriasis in patients with rheumatoid arthritis. *Semin Rheumat* 2020; 50: 36–41.

184. Lee WS, Choi YJ and Yoo WH. Use of tocilizumab in a patient with pyoderma gangrenosum and rheumatoid arthritis. *J Eur Acad Dermatol Venereol* 2017; 31: e75–e77.

185. Sieper J, Porter-Brown B, Thompson L, et al. Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials. *Ann Rheum Dis* 2014; 73: 95–100.

186. Sieper J, Braun J, Kay J, et al. Sarilumab for the treatment of ankylosing spondylitis: results of a phase II, randomised, double-blind, placebo-controlled study (ALIGN). *Ann Rheum Dis* 2015; 74: 1051–1057.

187. Madureira P, Pimenta SS, Bernardo A, et al. Off-label use of tocilizumab in psoriatic arthritis:
case series and review of the literature. Acta Reumatol Port 2016; 41: 251–255.

188. Ogata A, Umeaki N, Katayama I, et al. Psoriatic arthritis in two patients with an inadequate response to treatment with tocilizumab. Joint Bone Spine 2012; 79: 85–87.

189. Johnston A, Xing X, Guzman AM, et al. IL-1F5, -F6, -F8, and -F9: a novel IL-1 family signaling system that is active in psoriasis and promotes keratinocyte antimicrobial peptide expression. J Immunol 2011; 186: 2613–2622.

190. Boutet MA, Bart G, Penhoat M, et al. Distinct expression of interleukin (IL)-36α, β and γ, their antagonist IL-36Ra and IL-38 in psoriasis, rheumatoid arthritis and Crohn’s disease. Clin Exp Immunol 2016; 184: 159–173.

191. Gresnigt MS, Rosler B, Jacobs CW, et al. Interleukin-36 receptor pathway regulates Aspergillus fumigatus-induced Th1 and Th17 responses. Eur J Immunol 2016; 41: 416–426.

192. Boutet MA, Nerviani A, Lliso-Ribera G, et al. Interleukin-36 family dysregulation drives joint inflammation and therapy response in psoriatic arthritis. Rheumatology (Oxford) 2020; 59: 828–838.

193. Kivelevitch D, Frieder J, Watson I, et al. Pharmacotherapeutic approaches for treating psoriasis in difficult-to-treat areas. Expert Opin Pharmacother 2018; 19: 561–575.

194. Ghoreschi K, Laurence A and O’Shea JJ. Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis. Br J Dermatol 2013; 169: 137–145.

195. Valor-Mendez L, Sticherling M, Kleyer A, et al. Successful treatment of refractory palmoplantar psoriasis in a psoriatic arthritis patient with the JAK inhibitor tofacitinib. Clin Exp Rheumatol. Epub ahead of print 5 August 2020. PMID: 32828149.

196. Solimani F, Hilke FJ and Ghoreschi K. Tofacitinib shows benefit in conjunction with other therapies in recalcitrant hidradenitis suppurativa patients. JAMA Dermatol 2020; 16: 99–102.

197. van der Heijde D, Song IH, Pangan AL, et al. efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial. Lancet 2019; 394: 2108–2117.

198. Nasifoglu S, Heinrich B and Welzel J. Successful therapy for pyoderma gangrenosum with a Janus kinase 2 inhibitor. Br J Dermatol 2018; 179: 504–505.

199. Merola JF, Papp KA, Nash P, et al. Tofacitinib in psoriatic arthritis patients: skin signs and symptoms and health-related quality of life from two randomized phase 3 studies. J Eur Acad Dermatol Venereol. Epub ahead of print 9 April 2020. DOI: 10.1111/jdv.16433.

200. Gregory MH, Ciorda MA, Deepak P, et al. Successful treatment of pyoderma gangrenosum with concomitant tofacitinib and infliximab. Inflamm Bowel Dis 2019; 25: e87–e88.

201. van der Heijde D, Deodhar A, Wei JC, et al. Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study. Ann Rheum Dis 2017; 76: 1340–1347.

202. Rash P, Coates LC, Kivitz AJ, et al. Safety and efficacy of tofacitinib in patients with active psoriatic arthritis: interim analysis of OPAL balance, an open-label, long-term extension study. Rheumatol Ther 2020; 7: 553–580.
211. Papp K, Pariser D, Catlin M, et al. A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis. Br J Dermatol 2015; 173: 767–776.

212. AbbVie. RINVOQ™ (upadacitinib) meets primary and key secondary endpoints in phase 3 study in psoriatic arthritis [press release]. https://news.abbvie.com/news/press-releases/rinvoq-upadacitinib-meets-primary-and-key-secondary-endpoints-in-phase-3-study-in-psoriatic-arthritis. htm (accessed 15 March 2020)

213. Kragstrup TW, Adams M, Lomholt S, et al. IL-12/IL-23p40 identified as a downstream target of apremilast in ex vivo models of arthritis. Ther Adv Musculoskelet Dis 2019; 11: 1759720X19828669.

214. Bissonnette R, Haydey R, Rosoph LA, et al. Apremilast for the treatment of moderate-to-severe palmoplantar psoriasis: results from a double-blind, placebo-controlled, randomized study. J Eur Acad Dermatol Venereol 2018; 32: 403–410.

215. Rich P, Gooderham M, Bachelez H, et al. Apremilast for the treatment of mild-to-moderate hidradenitis suppurativa associated with psoriatic arthritis in multimorbid patients: case report and review of literature. Medicine (Baltimore) 2020; 99: e18991.

216. Wells AF, Edwards CJ, Kivitz AJ, et al. Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial. Rheumatology (Oxford) 2018; 57: 1253–1263.

217. Mease P, Genovese MC, Gladstein G, et al. Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheum 2011; 63: 939–948.

218. Song IH, Heldmann F, Rudwaleit M, et al. Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study. Ann Rheum Dis 2011; 70: 1108–1110.

219. Ye C and Li W. Cutaneous vasculitis in a patient with ankylosing spondylitis: a case report. Medicine (Baltimore) 2019; 98: e14121.

220. Enginar AU, Nur H and Kacar C. Coexistence of ankylosing spondylitis and discoid lupus: a case report. North Clin Istamb 2019; 6: 412–414.
231. Goncalves MJ, Romao VC, Soares-de-Almeida L, et al. Erythema elevatum diutinum in Crohn’s disease-associated spondyloarthritis - a rare vasculitis, an unusual association. *Acta Reumatol Port* 2017; 42: 324–328.

232. Gottlieb A, Natsis NE, Kerdel F, et al. A phase II open-label study of bermekimab in patients with hidradenitis suppurativa shows resolution of inflammatory lesions and pain. *J Invest Dermatol* 2020; 140: 1538–1545.e2.

233. Sung YK and Lee YH. Comparative study of the efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib versus methotrexate for disease-modifying antirheumatic drug-naive patients with rheumatoid arthritis. *Z Rheumatol*. Epub ahead of print 24 September 2020. DOI: 10.1007/s00393-020-00889-x.